Breakthrough
Medical Research

Impact Stories

Accelerating Breakthrough Medical Research

More than 6 million Americans have Alzheimer's, and that number is increasing rapidly. The Tuchman Family Foundation has made a sizable multi-year commitment to the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the discovery of drugs to help prevent, treat and cure this devastating disease. 


ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, and it has awarded more than $168 million to fund over 650 Alzheimer's drug discovery and biomarker programs and clinical trials in 19 countries. Its venture philanthropy model funds the most high-risk/high-reward promising research from both academia and biotech companies worldwide, making investments rather than grants, and reinvesting all returns into the science.

 

This strategy has also enabled the ADDF to fund and bring new diagnostic tools to market, like the Amyvid PET scan which revolutionized the field of Alzheimer’s drug discovery; and in 2020, the very first blood test for Alzheimer’s is also expected to have a dramatic impact on drug discovery and beyond.


Accelerating Breakthrough Medical Research

More than 6 million Americans have Alzheimer's, and that number is increasing rapidly. The Tuchman Family Foundation has made a sizable multi-year commitment to the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the discovery of drugs to help prevent, treat and cure this devastating disease. 


ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, and it has awarded more than $168 million to fund over 650 Alzheimer's drug discovery and biomarker programs and clinical trials in 19 countries. Its venture philanthropy model funds the most high-risk/high-reward promising research from both academia and biotech companies worldwide, making investments rather than grants, and reinvesting all returns into the science.

 

This strategy has also enabled the ADDF to fund and bring new diagnostic tools to market, like the Amyvid PET scan which revolutionized the field of Alzheimer’s drug discovery; and in 2020, the very first blood test for Alzheimer’s is also expected to have a dramatic impact on drug discovery and beyond.

Results

650+ Trials
& Programs

FUNDED IN BIOMARKERS AND DRUG DISCOVERY

Alzheimer's
Blood Test

BROUGHT AMYVID PET SCAN TO MARKET



SUPPORTING BREAKTHROUGH MEDICAL RESEARCH IN

19 Countries


Imagining a World Free from Devastating Diseases

National Jewish Health (NJH), the nation’s leading respiratory hospital, impacts the lives of countless individuals with respiratory, cardiac, immune and related diseases. The Tuchman Family Foundation’s longstanding support of NJH provides resources to save and improve the lives of patients, conduct disease research, and set the standard of care to benefit countless individuals across the world.


With the establishment of The Tuchman Family Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health is home to a pulmonary team that is among the largest specialty groups in the nation for diagnosing and treating adults with a variety of common, unusual and complex respiratory diseases and sleep disorders, including: chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, interstitial lung diseases and pulmonary hypertension among other conditions. 


The Tuchman Family Foundation also helps to underwrite the organization’s Campaign for National Jewish Health, the innovative Center for Outpatient Health, along with other strategic endeavors. Opened to patients in fall 2021, the Center for Outpatient Health is a state-of-the-art respiratory and related disease diagnostic and treatment center that is enhancing National Jewish Health’s ability to serve patients while providing more space for growth, education and research in existing facilities



Imagining a World Free from Devastating Diseases

National Jewish Health (NJH), the nation’s leading respiratory hospital, impacts the lives of countless individuals with respiratory, cardiac, immune and related diseases. The Tuchman Family Foundation’s longstanding support of NJH provides resources to save and improve the lives of patients, conduct disease research, and set the standard of care to benefit countless individuals across the world.


With the establishment of The Tuchman Family Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health is home to a pulmonary team that is among the largest specialty groups in the nation for diagnosing and treating adults with a variety of common, unusual and complex respiratory diseases and sleep disorders, including: chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, interstitial lung diseases and pulmonary hypertension among other conditions. 


The Tuchman Family Foundation also helps to underwrite the organization’s Campaign for National Jewish Health, the innovative Center for Outpatient Health, along with other strategic endeavors. Opened to patients in fall 2021, the Center for Outpatient Health is a state-of-the-art respiratory and related disease diagnostic and treatment center that is enhancing National Jewish Health’s ability to serve patients while providing more space for growth, education and research in existing facilities

Results

National Presence +
Global Reach

24 COLORADO LOCATIONS with partnerships in NEW YORK AND PHILadephia to treat global patients


Ranked
#1 or #2

PULMONOLOGY AND
LUNG SURGERY BY US NEWS & WORLD REPORT FOR 25 CONSECUTIVE YEARS



Over Five

Areas of Care

SETTING NATIONAL
STANDARDS




Share by: